Avastin Plus Commonly Used Chemotherapies Improved...
Jun 1, 2009 | Posted by: roboblogger | Full story: BioResearch Online
Genentech, Inc. today announced results of a Phase III study that showed Avastin plus commonly used chemotherapies, including capecitabine and anthracycline-based therapies, increased the time women receiving first-line therapy for advanced HER2-negative breast cancer lived without the disease worsening , compared to the chemotherapies alone.
|Zelboraf Ripoff of Melanoma Patients (Nov '11)||Nov '13||Ye li||4|
|Tarceva meets goal in first-line lung cancer trial (Nov '08)||Nov '13||Avi||5|
|Studies: Avastin may fight early breast cancers (Mar '12)||Sep '13||Sabastian||2|
|Questions Swirl Around Avastin (Jun '09)||Sep '13||Jesus||2|
|FDA clears Genentech drug for kidney cancer (Aug '09)||Sep '13||Elvin||2|
|FDA alerts doctors to fatal case of rare brain ... (Sep '08)||Sep '13||Kendrick||10|
|FDA Approves Genentech's Kadcyla (Ado-Trastuzum... (May '13)||May '13||Martin||2|